Jazz Pharmaceuticals plc

NasdaqGS:JAZZ 株式レポート

時価総額：US$7.1b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Jazz Pharmaceuticals 将来の成長

Future 基準チェック /36

Jazz Pharmaceuticals利益と収益がそれぞれ年間19.6%と5.8%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に22.8% 18.6%なると予測されています。

主要情報

19.6%

収益成長率

18.6%

EPS成長率

Pharmaceuticals 収益成長27.6%
収益成長率5.8%
将来の株主資本利益率22.8%
アナリストカバレッジ

Good

最終更新日06 Jun 2024

今後の成長に関する最新情報

Recent updates

Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off

Apr 15

Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Apr 02
Insufficient Growth At Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Hampers Share Price

Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Feb 18
Is Jazz Pharmaceuticals (NASDAQ:JAZZ) A Risky Investment?

Updated View On Jazz Pharmaceuticals' 2025 Goals

Jan 29

Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Dec 26
Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) Price Is Right But Growth Is Lacking

Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Oct 31
Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

Jul 12
Does Jazz Pharmaceuticals (NASDAQ:JAZZ) Have A Healthy Balance Sheet?

We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Apr 12
We Think Jazz Pharmaceuticals (NASDAQ:JAZZ) Can Stay On Top Of Its Debt

Jazz Pharmaceuticals: Monopoly In The Narcolepsy Drug Market

Aug 24

Jazz begins phase 3 trial of cannabis drug Epidiolex for rare epilepsy

Aug 18

Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Aug 10
Jazz Pharmaceuticals (NASDAQ:JAZZ) Seems To Use Debt Quite Sensibly

Jazz Pharmaceuticals: Strong Launch Of Xywav In Idiopathic Hypersomnia

Jun 08

Jazz Pharmaceuticals (NASDAQ:JAZZ) Takes On Some Risk With Its Use Of Debt

May 12
Jazz Pharmaceuticals (NASDAQ:JAZZ) Takes On Some Risk With Its Use Of Debt

業績と収益の成長予測

NasdaqGS:JAZZ - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/20264,5986531,6001,49516
12/31/20254,3685981,3681,49619
12/31/20244,0534321,1991,32119
3/31/20243,8433319831,039N/A
12/31/20233,8344151,0491,092N/A
9/30/20233,794808671,267N/A
6/30/20233,763-879871,377N/A
3/31/20233,738-1569181,384N/A
12/31/20223,659-2247741,272N/A
9/30/20223,584-199841,108N/A
6/30/20223,481-52809964N/A
3/31/20223,300-450622702N/A
12/31/20213,094-330733779N/A
9/30/20212,863-161711787N/A
6/30/20212,62640708771N/A
3/31/20212,436518750912N/A
12/31/20202,364239520900N/A
9/30/20202,280179455801N/A
6/30/20202,217133478881N/A
3/31/20202,188280509847N/A
12/31/20192,162523594776N/A
9/30/20192,056609726907N/A
6/30/20191,988656676791N/A
3/31/20191,954486646834N/A
12/31/20181,891447667799N/A
9/30/20181,851520642785N/A
6/30/20181,793434530753N/A
3/31/20181,687447578696N/A
12/31/20171,619488N/A693N/A
9/30/20171,579372N/A669N/A
6/30/20171,541399N/A613N/A
3/31/20171,528408N/A605N/A
12/31/20161,488397N/A592N/A
9/30/20161,432363N/A531N/A
6/30/20161,399361N/A573N/A
3/31/20161,352335N/A587N/A
12/31/20151,325330N/A532N/A
9/30/20151,312328N/A545N/A
6/30/20151,278266N/A499N/A
3/31/20151,235222N/A434N/A
12/31/20141,17358N/A408N/A
9/30/20141,08132N/A353N/A
6/30/20141,00682N/A354N/A
3/31/201492380N/A287N/A
12/31/2013872216N/A288N/A
9/30/2013820327N/A314N/A
6/30/2013764285N/A227N/A

アナリストによる今後の成長予測

収入対貯蓄率: JAZZの予測収益成長率 (年間19.6% ) は 貯蓄率 ( 2.4% ) を上回っています。

収益対市場: JAZZの収益 ( 19.6% ) はUS市場 ( 14.8% ) よりも速いペースで成長すると予測されています。

高成長収益: JAZZの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: JAZZの収益 ( 5.8% ) US市場 ( 8.5% ) よりも低い成長が予測されています。

高い収益成長: JAZZの収益 ( 5.8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: JAZZの 自己資本利益率 は、3年後には高くなると予測されています ( 22.8 %)

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y